Ito R, Morio H, Baba T, Sakaguchi Y, Wakayama N, Isogai R
Pharm Res. 2022; 39(7):1575-1586.
PMID: 35288803
DOI: 10.1007/s11095-022-03189-y.
Del Frari L, Leaute-Labreze C, Guibaud L, Barbarot S, Lacour J, Chaumont C
Pharmacol Res Perspect. 2018; 6(3):e00399.
PMID: 29736244
PMC: 5925426.
DOI: 10.1002/prp2.399.
de Gomez Dumm I, de Alaniz M, Brenner R
Lipids. 2016; 13(10):649-52.
PMID: 27520107
DOI: 10.1007/BF02533740.
Fujito K, Takayanagi R, Kimura K, Yokoyama H, Yamada Y
Eur J Drug Metab Pharmacokinet. 2014; 41(2):157-67.
PMID: 25510848
DOI: 10.1007/s13318-014-0244-3.
Zahra R, Ahmad R, Asghar M, Ali A, Soghra K
Indian J Clin Biochem. 2012; 21(1):121-5.
PMID: 23105582
PMC: 3453752.
DOI: 10.1007/BF02913079.
Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment.
Thompson M, Beard D
J Pharm Sci. 2011; 101(1):424-35.
PMID: 21968734
PMC: 3314064.
DOI: 10.1002/jps.22768.
The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.
Mahmood I, Balian J
Clin Pharmacokinet. 1999; 36(1):1-11.
PMID: 9989339
DOI: 10.2165/00003088-199936010-00001.
Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding.
Cheng H, Gillespie W
J Pharmacokinet Biopharm. 1996; 24(4):389-402.
PMID: 9044167
DOI: 10.1007/BF02353519.
Scaling basic toxicokinetic parameters from rat to man.
Bachmann K, Pardoe D, White D
Environ Health Perspect. 1996; 104(4):400-7.
PMID: 8732950
PMC: 1469326.
DOI: 10.1289/ehp.96104400.
Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration.
Huang S, Chiou W
J Pharmacokinet Biopharm. 1981; 9(6):711-23.
PMID: 7341756
DOI: 10.1007/BF01070902.
Pharmacokinetics of propranolol.
Borgstrom L, Johansson C, Larsson H, Lenander R
J Pharmacokinet Biopharm. 1981; 9(4):419-29.
PMID: 7310641
DOI: 10.1007/BF01060886.
Altered plasma protein binding of drugs in thyroid disease.
Feely J, Stevenson I, Crooks J
Clin Pharmacokinet. 1981; 6(4):298-305.
PMID: 7249488
DOI: 10.2165/00003088-198106040-00004.
Plasma propranolol steady state concentrations in thyroid disorders.
Feely J, Crooks J, Stevenson I
Eur J Clin Pharmacol. 1981; 19(5):329-33.
PMID: 7238561
DOI: 10.1007/BF00544582.
Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat.
Igari Y, Sugiyama Y, AWAZU S, Hanano M
J Pharmacokinet Biopharm. 1982; 10(1):53-75.
PMID: 7069578
DOI: 10.1007/BF01059183.
Unaltered serum propranolol binding by meal-induced variations in fatty acids.
Naranjo C, Sellers E, Khouw V
Br J Clin Pharmacol. 1982; 13(4):575-6.
PMID: 7066174
PMC: 1402056.
DOI: 10.1111/j.1365-2125.1982.tb01425.x.
A standard approach to compiling clinical pharmacokinetic data.
Sheiner L, Benet L, Pagliaro L
J Pharmacokinet Biopharm. 1981; 9(1):59-127.
PMID: 7014827
DOI: 10.1007/BF01059343.
Influence of age on serum protein binding of propranolol.
Bendayan R, Pieper J, Stewart R, Caranasos G
Eur J Clin Pharmacol. 1984; 26(2):251-4.
PMID: 6723765
DOI: 10.1007/BF00630294.
Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.
Igari Y, Sugiyama Y, Sawada Y, Iga T, Hanano M
J Pharmacokinet Biopharm. 1983; 11(6):577-93.
PMID: 6678311
DOI: 10.1007/BF01059058.
Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.
Benedek I, Fiske 3rd W, GRIFFEN W, Bell R, Blouin R, McNamara P
Br J Clin Pharmacol. 1983; 16(6):751-4.
PMID: 6661365
PMC: 1428326.
DOI: 10.1111/j.1365-2125.1983.tb02258.x.
Prediction of the volumes of distribution of basic drugs in humans based on data from animals.
Sawada Y, Hanano M, Sugiyama Y, Harashima H, Iga T
J Pharmacokinet Biopharm. 1984; 12(6):587-96.
PMID: 6533294
DOI: 10.1007/BF01059554.
